SNP-810 (SafeTynadol) is a novel paracetamol formulation with a safety dosage range far exceeding that of all currently marketed paracetamol products. The product has undergone a series of rigorous preclinical and clinical studies, including pharmacokinetic assessments of toxic metabolite formation, serological monitoring, and liver function-related clinical evaluations. In the pivotal human study, subjects received daily doses equivalent to three times the standard safe dosage of SNP-810. Comprehensive evaluations, including pharmacokinetic analysis of toxic metabolites and monitoring of serological markers, confirmed safety. In this pivotal clinical trial, a total of 24 tablets (500 mg each) were administered without clinically significant hepatotoxic responses, nor were any acetaminophen-related abnormalities in liver function observed.

More details: https://sinewpharma.com/en/products-detail3-5.htm

SNP-810 is a next-generation non-hepatotoxic acetaminophen, breaking through the long-standing safety limitations of traditional formulations. It offers a significantly wider therapeutic window, reducing the risk of overdose while preserving analgesic efficacy and improving metabolic pathways. Ideal for diverse pain scenarios such as postoperative and chronic pain, SNP-810 has the potential to substantially reduce public health risks associated with acute liver failure.

Currently, there are no market competitors with comparable liver safety. With patents granted in multiple countries, SNP-810 has completed pivotal clinical trial, a total of 24 tablets (500 mg each) were administered without clinically significant hepatotoxic responses. It has the potential to modify or eliminate the FDA-required hepatotoxicity warning label, positioning it as a highly competitive option in the OTC (over-the-counter) analgesic market. Its broader safety margin enables it to seize substantial market share from existing analgesics, including NSAIDs, COX-2 inhibitors, and opioid combinations.